Lean and fat-mass changes following upfront docetaxel compared to androgen deprivation monotherapy in metastatic castration-naïve prostate cancer.

Thekkekara, Romy Jose; Pathak, Surabhi; Yadav, Udit; Ahmed, Ahmed T.; Mullane, Michael Russell; Batra, Kumar Kunnal; Lad, Thomas E.; Kato, Caroline; Psutka, Sarah P.

doi:10.1200/jco.2018.36.15_suppl.e17020

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published data on patients with metastatic hormone‐naïve prostate cancer are limited to a recent retrospective study 11 and an abstract 23 . Kashiwagi et al 11 studied 178 metastatic hormone‐naïve prostate cancer patients who received primary ADT and showed a higher psoas muscle ratio is a predictor of longer overall survival (HR = 0.45, p = .02) but not progression‐free survival.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 Published data on patients with metastatic hormone-naïve prostate cancer are limited to a recent retrospective study 11 and an abstract. 23 Kashiwagi et al 11 studied 178 metastatic hormonenaïve prostate cancer patients who received primary ADT and showed a higher psoas muscle ratio is a predictor of longer overall survival (HR = 0.45, p = .02) but not progression-free survival. The respective median follow-up, progression-free survival, and overall survival in the above study were 32 (range: 0-190 months), 28 months, and 80 months, with all-cause death, occurred in 33.7% of patients.…”

Section: Disease Progression According To Body Compositionmentioning

confidence: 99%

“…10,21,22 A detailed summary of these studies is provided in Table 3. [5][6][7][8][9][10]21,22 In almost all related studies except one, 23 the body composition was assessed at baseline (before the initiation of therapy). Thus, the effects of percentage change in body composition following therapy and survival outcomes remain to be evaluated.…”

Section: Disease Progression According To Body Compositionmentioning

confidence: 99%

“…The respective median follow-up, progression-free survival, and overall survival in the above study were 32 (range: 0-190 months), 28 months, and 80 months, with all-cause death, occurred in 33.7% of patients. 11 In a published abstract on 59 metastatic castration sensitive prostate cancer patients who received ADT with or without upfront docetaxel, Thekkekara et al 23 reported a significant decrease in skeletal muscle index, increase in fat-mass-index, and prevalence of sarcopenia following treatment. They reported a shorter time to progression in sarcopenic patients (p = .046).…”

Section: Disease Progression According To Body Compositionmentioning

confidence: 99%

See 3 more Smart Citations

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer

2020

View full text Add to dashboard Cite

Background The purpose of this study is to assess the body composition changes in men with recently diagnosed oligometastatic prostate cancer following neoadjuvant chemohormonal therapy. Further, we evaluated whether CT‐based body composition parameters are associated with biochemical recurrence or imaging progression. Material and methods Recently diagnosed castration‐naïve oligometastatic prostate cancer patients who received neoadjuvant docetaxel chemotherapy and androgen deprivation treatment (ADT) before prostatectomy and consolidation of local and oligometastatic disease (total eradication therapy), as part of a phase‐II prospective clinical trial were included. Body composition parameters including cross‐sectional areas of the psoas muscle, total, visceral, and subcutaneous adipose tissue were measured on serial CT scans obtained before and following completion of neoadjuvant treatment. Results A total of 22 prostate cancer patients were included (median age 58 years, median Gleason score 8). The median time intervals between commencement of neoadjuvant chemohormonal therapy and first and second follow‐up CTs were 3 and 12 months, respectively. Compared to the baseline scan, there were significant declines in psoas muscle cross‐sectional areas with estimated percentage declines of −13.9% (IQR: 7.6%–16.5%, p < .001) and −13.2% (IQR: 6%–11.2%, p < .001) on first and second follow‐up CTs. There were significant increases in subcutaneous adipose tissue following neoadjuvant chemohormonal therapy with percentage increases of +8.9% (IQR: 5.1%–21.5%, p = .002) and +18.9% (IQR: 6.1%–33.8%, p < .001), respectively. The median follow‐up was 34.5 months. The estimated 2‐year prostate‐specific antigen progression‐free and radiologic progression‐free survival were 95.5%. No significant association between baseline or percentage change in body composition parameters and disease progression were identified. Conclusions Our findings showed a significant reduction in muscle mass and an increase in subcutaneous adiposity in men treated with neoadjuvant docetaxel and ADT, more pronounced on the first follow‐up scan after completion of neoadjuvant treatment. Body composition parameters were not found to be significant predictors of disease progression in our cohort.

show abstract

Section: Discussionmentioning

confidence: 99%